Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China · Delayed Price · Currency is CNY 4.640
-0.110 (-2.32%)
Nov 13, 2026, 3:04 PM CST
SHE:300039 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,853 | 6,307 | 6,464 | 6,956 | 8,431 | 6,443 | |
Market Cap Growth | -28.73% | -2.43% | -7.07% | -17.49% | 30.84% | 26.49% |
Enterprise Value | 3,543 | 4,673 | 5,145 | 6,224 | 6,828 | 5,042 |
Last Close Price | 4.64 | 5.92 | 5.94 | 6.28 | 7.55 | 5.72 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 20.65 | 22.64 | 17.21 | 21.22 | 44.19 | 45.99 |
Forward PE | - | 24.15 | 24.15 | 24.15 | 24.15 | 24.15 |
PS Ratio | 4.84 | 5.47 | 4.39 | 4.36 | 7.54 | 5.86 |
PB Ratio | 1.13 | 1.43 | 1.58 | 1.73 | 2.24 | 2.12 |
P/TBV Ratio | 1.17 | 1.48 | 1.64 | 1.75 | 2.27 | 2.16 |
P/FCF Ratio | 20.57 | 30.96 | 46.70 | 19.67 | 24.45 | 77.14 |
P/OCF Ratio | 18.96 | 27.34 | 23.17 | 18.18 | 22.40 | 51.11 |
PEG Ratio | - | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.53 | 4.05 | 3.49 | 3.91 | 6.10 | 4.58 |
EV/EBITDA Ratio | 14.02 | 15.73 | 13.16 | 17.92 | 32.02 | 32.91 |
EV/EBIT Ratio | 16.02 | 17.73 | 14.49 | 20.09 | 37.62 | 42.25 |
EV/FCF Ratio | 15.01 | 22.94 | 37.17 | 17.60 | 19.80 | 60.36 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | - | - | - |
Debt / EBITDA Ratio | 0.02 | 0.01 | 0.01 | - | - | - |
Debt / FCF Ratio | 0.02 | 0.02 | 0.04 | - | - | - |
Net Debt / Equity Ratio | -0.30 | -0.36 | -0.41 | -0.19 | -0.22 | -0.48 |
Net Debt / EBITDA Ratio | -5.19 | -5.35 | -4.33 | -2.16 | -3.90 | -9.49 |
Net Debt / FCF Ratio | -5.55 | -7.80 | -12.23 | -2.13 | -2.41 | -17.41 |
Asset Turnover | 0.21 | 0.25 | 0.32 | 0.36 | 0.29 | 0.35 |
Inventory Turnover | 0.91 | 1.15 | 1.52 | 1.88 | 1.52 | 1.31 |
Quick Ratio | 8.90 | 12.12 | 9.49 | 3.86 | 4.72 | 10.85 |
Current Ratio | 10.49 | 13.41 | 10.40 | 4.41 | 5.32 | 11.82 |
Return on Equity (ROE) | 5.30% | 6.53% | 9.22% | 8.39% | 5.59% | 4.98% |
Return on Assets (ROA) | 2.87% | 3.54% | 4.88% | 4.38% | 2.98% | 2.39% |
Return on Invested Capital (ROIC) | 6.33% | 8.68% | 10.77% | 8.50% | 6.75% | 7.18% |
Return on Capital Employed (ROCE) | 4.90% | 5.70% | 8.30% | 7.30% | 4.60% | 3.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.84% | 4.42% | 5.81% | 4.71% | 2.26% | 2.17% |
FCF Yield | 4.86% | 3.23% | 2.14% | 5.08% | 4.09% | 1.30% |
Dividend Yield | 4.31% | 2.16% | 1.62% | 1.50% | 0.74% | 0.81% |
Payout Ratio | 57.85% | 48.83% | 27.85% | 19.14% | 27.41% | 22.59% |
Buyback Yield / Dilution | -0.02% | -0.02% | -0.00% | 0.02% | -0.01% | -0.04% |
Total Shareholder Return | 4.29% | 2.13% | 1.61% | 1.53% | 0.74% | 0.77% |